USFDA completes inspection at API manufacturing facility of Aurobindo Pharma’s arm

30 Sep 2024 Evaluate

The United States Food and Drug Administration (USFDA) has completed inspection at Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma’s Unit-II, an API manufacturing facility situated at Telangana. The USFDA had conducted an inspection from September 23, 2024 to September 27, 2024 at this facility.

The inspection closed with 10 observations. The observations are of procedural in nature and will be responded to within the stipulated time.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1240.70 -14.70 (-1.17%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.